加州太平洋生物科学公司 PACB 深 沪
等待开盘 07-17 09:30:00 美东时间
1.49
+0.050
+3.47%
华盛通- 最 高1.62
- 今 开1.47
- 成交量 1345.03万股
- 最 低 1.43
- 昨 收 1.44
- 总市值 4.47亿
- 52周最高 2.72
- 市盈率 静 --
- 换手率 4.48%
- 52周最低 0.8511
- 委 比 -4.03%
- 总股本 3.00亿
- 历史最高 53.69
- 量 比 2.43
- 振 幅 13.19%
- 历史最低 0.8511
- 每 手 1
- 风险率 2.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock
Ratings for Pacific Biosciences (NASDAQ:PACB) were provided by 4 analysts in th...
06-25 22:01
Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $2 to $1.5.
06-25 21:56
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 15.2% to $0.71 durin...
06-14 05:05
Target ALS Partners With PacBio To Launch Largest Global Whole Genome Sequencing Initiative For ALS To Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwideNEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/
06-02 22:05
美股牛股 | 生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功
生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功；Joby Aviation大涨28%，获丰田汽车2.5亿美元战略投资>>
05-29 19:18
PacBio to Present at Upcoming Investor Conferences
PacBio announced that its management will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, and the 46th Annual Goldman Sachs Global Healthcare Conference on June 11, 2025. Live webcasts will be available on the company's investor page, with replays accessible for 30 days. PacBio is a leading life science technology company specializing in high-quality sequencing solutions.
05-28 13:00
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target
Stephens & Co. analyst Mason Carrico reiterates Pacific Biosciences (NASDAQ:PACB) with a Overweight and maintains $1.8 price target.
05-15 21:36
